- Veeva Systems (NYSE:VEEV) said Regeneron Pharmaceuticals and Biogen have selected Veeva Vault CRM for their global operations in new partnerships.
- The agreements expand adoption of Veeva’s AI powered commercial platform among large pharmaceutical companies.
- The new deals follow earlier news on Eli Lilly’s commitment to Vault CRM and changes in Veeva’s sales leadership.
Readers watching Veeva’s AI driven software footprint in life sciences may also want to review other stocks tied to the build out of AI infrastructure through 55 AI infrastructure stocks.
Veeva Systems, a US based healthcare software company with a market cap of about $40.4b, provides cloud tools that help life sciences companies manage customer relationships and regulated content across global markets including North America, Europe and the Asia Pacific.
3 things going right for Veeva Systems that this headline doesn’t cover.
How do the Regeneron and Biogen wins fit into Veeva Systems’ strategy?
Regeneron and Biogen committing to Veeva Vault CRM globally helps Veeva Systems deepen its role as a commercial system of record for large pharma. Both are using AI powered field engagement and the Agentic Call Report, which aligns with Veeva’s push toward an agentic commercial model built on its Vault CRM Suite.
Does this news change the current Veeva Systems Narrative?
This news lines up closely with the Narrative’s catalyst that large pharma customers are consolidating more spend on Veeva’s Commercial Cloud as AI agents are embedded into Vault. It supports the idea that interoperability progress and AI integration can drive broader suite adoption, while customer concentration risk remains an important counterpoint to track.
If we take a look at the community Narrative for Veeva Systems, we can see how this news fits into the bigger investment story.
What should investors watch next to see if these CRM deals really matter for Veeva Systems?
The key test is whether these contracts translate into broader Vault CRM Suite rollouts and AI agent usage over the next few quarters, rather than just initial deployments. Investors can watch for evidence of multi product expansions, references to Commercial Evidence usage, and updates on top 20 pharma adoption in upcoming earnings calls.
For the full picture including more risks and rewards, check out the complete Veeva Systems analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New:Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks
Have feedback on this article? Concerned about the content? Get in touch with us directly.Alternatively, email editorial-team@simplywallst.com
MI
mitchell_lawler
The Foxhole
Is Nvidia actually expensive at 32 times earnings? I think that number can melt faster than people realise.
Why would I fret over Nvidia results now? I think it’s moment has gone. I will invert and see what companies can be the next Nvidia.
Multiple has already melted 50 percent in the last year. It can melt another 50 percent from here in the next year?
Mitchell Lawler
Market Insights
Which payment stocks actually get paid?
Every new payment app was supposed to kill Visa and Mastercard. Instead, they got bigger. So what does that mean for the payment stocks on your radar?
42
Aug 20, 2026
About NYSE:VEEV
Veeva Systems
Provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America.
Flawless balance sheet with solid track record.
Similar Companies
Market Insights
Which payment stocks actually get paid?MI
Mitchell Lawler
Picking portfolio winners takes more than hot airAN
Andrew Legget
What Korea’s market says about your index fundMI
Mitchell Lawler
Advertisement
Weekly Picks
Rick_Orfordon Starfighters Space·20 days ago
The 1960s Fighter Jet That Could Crack Open a $20 Billion Satellite Market
Fair Value:US$522.8% undervalued
69followersusers have followed this narrative
·4commentsusers have commented on this narrative
·11likesusers have liked this narrative
TR
tripledubon Meta Platforms·22 days ago
The $135 Billion Bet That Should Make Every Shareholder Nervous
Taloson Voyager Technologies·17 days ago
The “Landlord of Orbit” – A Deep Value Play Ahead of the Starlab Era
Ivoedon Uber Technologies·11 days ago
Uber’s Valuation Depends On Who Captures The Economics Of Driverless Rides
RecentlyUpdated Narratives
AstrisCorporateAdvisoryon Restar·about 3 hours ago
Monitoring next steps
Fair Value:JP¥2.59k96.7% overvalued
1followerusers have followed this narrative
·0commentsusers have commented on this narrative
·0likesusers have liked this narrative
PR
prajeeshprathapon Medpace Holdings·about 3 hours ago
Why Medpace Outperforms Competitors in the Mid-Sized Biotech Niche
AstrisCorporateAdvisoryon Polaris Holdings·about 3 hours ago
Share gains to fuel earnings momentum
Popular Narratives
oscargarciaon NVIDIA·3 months ago
The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.
CubanEroson Microsoft·about 2 months ago
A wonderful business at reasonable price.
Fair Value:US$419.9117.1% overvalued
206followersusers have followed this narrative
·0commentsusers have commented on this narrative
·9likesusers have liked this narrative
KI
KiwiInveston Amazon.com·4 months ago
